non-small cell lung cancer

Advaxis Doses First Patient With Customized Immunotherapy Targeting Personal Neoantigens
Advaxis Doses First Patient With Customized Immunotherapy Targeting Personal Neoantigens
CP Wire
Advaxis
ADXS-NEO
immunotherapy
non-small cell lung cancer
clinical trials
Flag link:
ASCO18: 3 unanswered questions from oncology's largest conference
ASCO18: 3 unanswered questions from oncology's largest conference
Biopharma Dive
ASCO 2018
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
immunotherapy combinations
non-small cell lung cancer
Flag link:
FDA Grants Pfizer's Xalkori Breakthrough Therapy Status for Two New Indications
Pfizer
Xalkori
non-small cell lung cancer
anaplastic large-cell lymphoma
Flag link:
BMY Is Rapidly Advancing Its First-Line NSCLC Research Program
BMY Is Rapidly Advancing Its First-Line NSCLC Research Program
Market Realist
Bristol-Myers Squibb
Opdivo
non-small cell lung cancer
Yervoy
Flag link:
AstraZeneca Announces Positive Results for Imfinzi in Non-Small Cell Lung Cancer
AstraZeneca Announces Positive Results for Imfinzi in Non-Small Cell Lung Cancer
CP Wire
AstraZeneca
MedImmune
Imfinzi
non-small cell lung cancer
Flag link:
AstraZeneca Announces Positive Results for Imfinzi in Non-Small Cell Lung Cancer
AstraZeneca
Imfinzi
non-small cell lung cancer
Flag link:
Rain Therapeutics nets $18M to push lung cancer asset into phase 2
Rain Therapeutics nets $18M to push lung cancer asset into phase 2
Fierce Biotech
Rain Therapeutics
non-small cell lung cancer
Flag link:
Neon Therapeutics Treats First Patient in Ph Ib Trial Evaluating Personal Cancer Vaccine NEO-PV-01 Plus Keytruda/Chemo Combination
Neon Therapeutics
cancer vaccines
NEO-PV-01
non-small cell lung cancer
Flag link:
EMA Validates Bristol-Myers Squibb’s Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic Non-Small Cell Lung Cancer
Bristol-Myers Squibb
non-small cell lung cancer
Opdivo
Yervoy
Flag link:
Mirati Therapeutics Announces Positive Results in Immuno-Oncology Combination Trials
Mirati Therapeutics Announces Positive Results in Immuno-Oncology Combination Trials
CP Wire
Mirati Therapeutics
Opdivo
checkpoint inhibitors
non-small cell lung cancer
Flag link:
Mirati Therapeutics Announces Positive Results in Immuno-Oncology Combination Trials
Mirati Therapeutics
Opdivo
checkpoint inhibitors
non-small cell lung cancer
Flag link:
Roche Receives FDA Approval for New Indication for cobas EGFR Mutation Test v2 as a Companion Diagnostic With Tagrisso
Roche Receives FDA Approval for New Indication for cobas EGFR Mutation Test v2 as a Companion Diagnostic With Tagrisso
CP Wire
Roche
cobas EGFR Mutation Test
Tagrisso
non-small cell lung cancer
AstraZeneca
Flag link:
Roche Receives FDA Approval for New Indication for cobas EGFR Mutation Test v2 as a Companion Diagnostic With Tagrisso
Roche
Tagrisso
non-small cell lung cancer
Flag link:
Merck, Bristol-Myers cancer drugs both beat expectations, but Merck beats them a little more
Merck, Bristol-Myers cancer drugs both beat expectations, but Merck beats them a little more
CNBC
Merck
Bristol-Myers Squibb
Keytruda
Opdivo
Yervoy
non-small cell lung cancer
AACR
Flag link:
We're about to get some key lung cancer data — and it could affect how hundreds of thousands of cancer patients are treated
We're about to get some key lung cancer data — and it could affect how hundreds of thousands of cancer patients are treated
San Francisco Gate, CA
lung cancer
cancer
Merck
Roche
Bristol-Myers Squibb
AACR
non-small cell lung cancer
Flag link:
AstraZeneca's (AZN) Imfinzi Gets FDA Nod for Label Expansion
AstraZeneca's (AZN) Imfinzi Gets FDA Nod for Label Expansion
Yahoo/Zacks.com
AstraZeneca
FDA
Imfinzi
non-small cell lung cancer
Flag link:
AstraZeneca's Tagrisso Label Expansion Filing Accepted by FDA
AstraZeneca's Tagrisso Label Expansion Filing Accepted by FDA
Yahoo/Zacks.com
AstraZeneca
Tagrisso
FDA
labeling
non-small cell lung cancer
Flag link:
Most Damaging Clinical Trial Failure: AstraZeneca's MYSTIC
Most Damaging Clinical Trial Failure: AstraZeneca's MYSTIC
BioPharma Dive
clinical trials
AstraZeneca
Mystic
Imfinzi
non-small cell lung cancer
Flag link:
Recent Developments for Merck’s Keytruda
Recent Developments for Merck’s Keytruda
Market Realist
Merck
Keytruda
immuno-oncology
anti-PD-1 immunotherapy
non-small cell lung cancer
Flag link:
AstraZeneca touts Tagrisso's CNS benefit
AstraZeneca touts Tagrisso's CNS benefit
BioPharma Dive
Tagrisso
AstraZeneca
non-small cell lung cancer
CNS metastases
Flag link:

Pages